Cargando…

Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1

Vanicosides A and B are the esters of hydroxycinnamic acids with sucrose, occurring in a few plant species from the Polygonaceae family. So far, vanicosides A and B have not been evaluated for anticancer activity against human malignant melanoma. In this study, we tested these two natural products,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nawrot-Hadzik, Izabela, Choromańska, Anna, Abel, Renata, Preissner, Robert, Saczko, Jolanta, Matkowski, Adam, Hadzik, Jakub
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370030/ https://www.ncbi.nlm.nih.gov/pubmed/32610527 http://dx.doi.org/10.3390/ijms21134611

Ejemplares similares

Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors–Molecular Docking and In Vitro Study
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2021)

Antiglycoxidative Properties of Extracts and Fractions from Reynoutria Rhizomes
por: Dołowacka-Jóźwiak, Arleta, et al.
Publicado: (2021)

In Vitro Gingival Wound Healing Activity of Extracts from Reynoutria japonica Houtt Rhizomes
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2021)

Phytochemical Diversity in Rhizomes of Three Reynoutria Species and their Antioxidant Activity Correlations Elucidated by LC-ESI-MS/MS Analysis
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2019)

Phenolic Compounds of Reynoutria sp. as Modulators of Oral Cavity Lactoperoxidase System
por: Magacz, Marcin, et al.
Publicado: (2021)

Chemical Composition of East Asian Invasive Knotweeds, their Cytotoxicity and Antimicrobial Efficacy Against Cariogenic Pathogens: An In-Vitro Study
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2019)

Oral Wound Healing Potential of Polygoni Cuspidati Rhizoma et Radix Decoction—In Vitro Study
por: Hadzik, Jakub, et al.
Publicado: (2023)

Proanthocyanidins and Flavan-3-ols in the Prevention and Treatment of Periodontitis—Immunomodulatory Effects, Animal and Clinical Studies
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2021)

Proanthocyanidins and Flavan-3-Ols in the Prevention and Treatment of Periodontitis—Antibacterial Effects
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2021)

Inhibition of Glycation-induced Cytotoxicity, Protein Glycation, and Activity of Proteolytic Enzymes by Extract from Perovskia atriplicifolia Roots
por: Miroliaei, Mehran, et al.
Publicado: (2017)

Betulin and Its Derivatives Reduce Inflammation and COX-2 Activity in Macrophages
por: Szlasa, Wojciech, et al.
Publicado: (2022)

Reynoutria sachalinensis extract elicits SA-dependent defense responses in courgette genotypes against powdery mildew caused by Podosphaera xanthii
por: Margaritopoulou, Theoni, et al.
Publicado: (2020)

Short (6 mm) and Regular Dental Implants in the Posterior Maxilla–7-Years Follow-up Study
por: Hadzik, Jakub, et al.
Publicado: (2021)

New panel of biomarkers to discriminate between amelanotic and melanotic metastatic melanoma
por: Militaru, Ioana V., et al.
Publicado: (2023)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

The effect of sulindac on redox homeostasis and apoptosis-related proteins in melanotic and amelanotic cells
por: Miliński, Maciej, et al.
Publicado: (2023)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
por: Hamis, Sara J., et al.
Publicado: (2021)

Pterostilbene-Mediated Inhibition of Cell Proliferation and Cell Death Induction in Amelanotic and Melanotic Melanoma
por: Wawszczyk, Joanna, et al.
Publicado: (2023)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Antimicrobial Efficacy of Different Decontamination Methods as Tested on Dental Implants with Various Types of Surfaces
por: Kubasiewicz-Ross, Paweł, et al.
Publicado: (2020)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

HGG-47. DECREASED GROWTH VELOCITY WITH LONG TERM USE OF BRAFV600e AND MEK INHIBITION IN A PATIENT WITH ANAPLASTIC GANGLIOGLIOMA
por: Tran, Hung, et al.
Publicado: (2020)

Simultaneous Determination of Four Compounds, Campesterol, Emodin8-O-β-D-Glucopyranoside, Quercetin, and Isoquercitrin in Reynoutria sachalinensis by High-performance Liquid Chromatography-Diode Array Detector
por: Eom, Min Rye, et al.
Publicado: (2017)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells
por: Vitiello, Marianna, et al.
Publicado: (2017)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
por: Chen, Brenden, et al.
Publicado: (2012)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
por: Molaei, Mahsa, et al.
Publicado: (2016)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

The Assessment of Anti-Melanoma Potential of Tigecycline—Cellular and Molecular Studies of Cell Proliferation, Apoptosis and Autophagy on Amelanotic and Melanotic Melanoma Cells
por: Rok, Jakub, et al.
Publicado: (2023)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Overproduction of thrombopoietin by BRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis
por: Tanaka, Hiroki, et al.
Publicado: (2019)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
por: De Paolo, Raffaella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j71cqs0u4oraq0aro15r525bti